DPT Stats & Data
[Cl-].CCCN(CCC)CCc1cnc2ccccc12.[H+]AIAASKTUEVUIQM-UHFFFAOYSA-NReceptor Profile
Receptor Actions
Receptor Binding
History & Culture
1950–1968
DPT was first synthesized in 1950, with initial pharmacological testing conducted in dogs by 1954. The compound was formally described in scientific literature by 1959, and human trials during the 1960s confirmed its hallucinogenic properties. By 1968, DPT had been identified as a novel designer drug.
1973–1979
Formal therapeutic research with DPT was first reported in 1973, when investigators began exploring low intramuscular doses ranging from 15 to 30 milligrams as an adjunct to psychotherapy for patients with alcohol dependence. The compound's capacity to enhance memory recall, promote emotional expressiveness, and facilitate self-exploration—combined with its reliably short duration of action—made it an attractive candidate for therapeutic settings. Concurrent research examined higher intramuscular doses of 75 to 125 milligrams to facilitate peak experiences in terminally ill cancer patients. Stanislav Grof was among the researchers involved in these clinical trials. While preliminary findings showed some promise, the research program was never sufficiently developed to establish definitive conclusions regarding therapeutic efficacy. This work received mainstream media attention through a CBS 60 Minutes segment broadcast in the late 1970s.
1980–present
Beginning in the 1980s, reports of DPT use emerged that were largely connected to the Temple of the True Inner Light, a New York City-based religious organization that developed as an offshoot of the Native American Church. The Temple adopted DPT as its primary sacrament, referring to the compound as "a powerful Angel of the Host" and "the true flesh of God." The organization's theology holds that DPT and other entheogens represent physical manifestations of the divine. Congregants receive their communion through either smoking or oral consumption of the sacrament. Despite maintaining a public profile, the organization has reportedly operated without interference from federal drug enforcement agencies. The Temple represents a notable instance of sustained ceremonial use of a synthetic psychedelic compound within an organized religious framework in the United States.
Subjective Effect Notes
physical: At light to moderate doses, there is often a slight sense of anaesthetization and relaxation. As the dose increases, perceptions of heart rate increase and body tremors and loss of muscle control are often reported. DPT can range from strong euphoria and erotiscism to nausea and dysphoria even within the same trip.
Effect Profile
Curated + 264 ReportsStrong visuals, headspace, body load, and auditory effects
Duration Timeline
BluelightEmpirical Duration
Erowid ReportsCommunity Effects
TripSitTolerance & Pharmacokinetics
drugs.wikiTolerance Decay
General serotonergic psychedelic pattern inferred from community and classic literature: substantial tolerance for several days with return towards baseline over 1–2 weeks. DMT shows atypical rapid tolerance dynamics; DPT likely follows the more typical pattern due to its longer duration. Data quality: mixed (anecdotal + extrapolation).
Cross-Tolerances
Demographics
Gender Distribution
Age Distribution
Reports Over Time
Effect Analysis
Erowid + BluelightEffects aggregated from 258 experience reports (208 Erowid + 56 Bluelight)
Effect Sentiment Distribution
Confidence Distribution
Positive Effects 63
Adverse Effects 68
Dose-Response Correlation
How effect frequency changes across dose levels
View data table
| Effect | Light (n=36) | Common (n=35) | Strong (n=31) |
|---|---|---|---|
| Visual Distortions | 83.3% | 74.3% | 90.3% |
| Anxiety | 61.1% | 51.4% | 61.3% |
| Music Enhancement | 61.1% | 51.4% | 41.9% |
| Color Enhancement | 44.4% | 48.6% | 51.6% |
| Stimulation | 38.9% | 42.9% | 35.5% |
| Confusion | 25.0% | 42.9% | 41.9% |
| Dissociation | 25.0% | 25.7% | 41.9% |
| Nausea | 22.2% | 20.0% | 41.9% |
| Empathy | 30.6% | 40.0% | 16.1% |
| Auditory Effects | 38.9% | 28.6% | 22.6% |
| Tactile Enhancement | 38.9% | 28.6% | 32.3% |
| Euphoria | 38.9% | 28.6% | 29.0% |
| Closed-Eye Visuals | 36.1% | 31.4% | 29.0% |
| Introspection | 16.7% | 28.6% | 22.6% |
| Focus Enhancement | 25.0% | 22.9% | 19.4% |
Subjective Effect Ontology
Experience ReportsStructured effect tags extracted from 264 Erowid & Bluelight experience reports using a controlled vocabulary of 220+ canonical effects across 15 domains.
Auditory
Emotional
Visual
Dose–Effect Mapping
Experience ReportsHow reported effects shift across dose tiers, based on 208 experience reports.
| Effect | Light (n=36) | Common (n=35) | Strong (n=31) | |
|---|---|---|---|---|
| visual distortions | → | |||
| anxiety | → | |||
| music enhancement | ↓ | |||
| color enhancement | ↑ | |||
| stimulation | → | |||
| confusion | ↑ | |||
| dissociation | ↑ | |||
| nausea | ↑ | |||
| empathy | ↓ | |||
| auditory effects | ↓ | |||
| tactile enhancement | ↓ | |||
| euphoria | ↓ | |||
| closed-eye visuals | ↓ | |||
| introspection | ↑ | |||
| focus enhancement | ↓ | |||
| muscle tension | — | ↓ | ||
| hospital | ↑ | |||
| time distortion | → | |||
| ego dissolution | ↑ | |||
| body high | ↓ |
Showing top 20 of 34 effects
Risk Escalation
Sentiment AnalysisAverage frequency of positive vs adverse effects across dose tiers
View effect breakdown
Adverse Effects
| Effect | Light (n=36) | Common (n=35) | Strong (n=31) | Change |
|---|---|---|---|---|
| Anxiety | 0% | |||
| Confusion | +67% | |||
| Nausea | +88% | |||
| Muscle Tension | — | -42% | ||
| Increased Heart Rate | -22% | |||
| Pupil Dilation | — | -38% | ||
| Psychosis | +16% | |||
| Memory Suppression | — | +37% | ||
| Motor Impairment | -21% | |||
| Seizure | — | +73% | ||
| Headache | — | — | 0% | |
| Thought Loops | — | — | 0% | |
| Sweating | — | — | 0% | |
| Jaw Clenching | — | 1% |
Positive Effects
| Effect | Light (n=36) | Common (n=35) | Strong (n=31) | Change |
|---|---|---|---|---|
| Music Enhancement | -31% | |||
| Color Enhancement | +16% | |||
| Stimulation | -8% | |||
| Empathy | -47% | |||
| Tactile Enhancement | -16% | |||
| Euphoria | -25% | |||
| Introspection | +35% | |||
| Focus Enhancement | -22% | |||
| Body High | -41% | |||
| Creativity Enhancement | — | — | 0% | |
| Pain Relief | — | — | 0% |
Dosage Distribution
Dose distribution from experience reports
Insufflated
Intramuscular
Smoked
Oral
Real-World Dose Distribution
62K DosesFrom 273 individual dose entries
Rectal (n=14)
Insufflated (n=170)
Oral (n=16)
Intramuscular (n=27)
Smoked (n=26)
Intravenous (n=7)
Common Combinations
Most co-occurring substances in experience reports
Form / Preparation
Most common forms and preparations reported
Body-Weight Dosing
Dose relative to body weight from reports with weight data
Insufflated
Intramuscular
Smoked
Oral
Redose Patterns
Redosing behavior across 170 reports
Legal Status
| Country | Status | Notes |
|---|---|---|
| Belgium | Schedule I equivalent | Listed in Belgium's most restrictive controlled substance category, approximately equivalent to Schedule II under the United States system. Manufacturing, distribution, and possession are prohibited. |
| Germany | NpSG (Neue-psychoaktive-Stoffe-Gesetz) | Controlled under the New Psychoactive Substances Act as of July 18, 2019. Production and importation with intent to market, administration to others, and trading are criminally punishable. Possession is prohibited but not subject to criminal penalty. |
| Greece | Controlled substance | Became a controlled substance on February 18, 2003 under national drug legislation. |
| Japan | Designated Substance (Shitei-Yakubutsu) | Controlled under the Pharmaceutical Affairs Law. Possession and sale are prohibited. |
| Latvia | Schedule I | Classified as a Schedule I controlled substance under national drug legislation. Possession, distribution, and production are illegal. |
| New Zealand | Class C | Controlled as a Class C substance due to its structural relationship to DMT, which is explicitly scheduled. The analogue provisions extend control to structurally similar tryptamines. |
| Portugal | Table II-A | Listed in Table II-A of the controlled substances tables alongside substances such as MDMA and LSD. Production and trafficking remain illegal; personal possession of small quantities is decriminalized under Portuguese drug policy. |
| Sweden | Narcotic substance | Classified as a narcotic substance on January 26, 2016 following its sale as a designer drug. Manufacturing, trade, and possession are prohibited. |
| Switzerland | Verzeichnis E | Specifically named as a controlled substance under Verzeichnis E (Schedule E) of Swiss narcotics legislation. Unauthorized possession, production, and distribution are prohibited. |
| United Kingdom | Class A | Controlled under the Misuse of Drugs Act 1971 through the tryptamine catch-all clause, which covers compounds structurally derived from tryptamine by substitution at the nitrogen atom of the sidechain with alkyl substituents. Class A classification carries the most severe penalties for possession, production, and distribution. |
| United States | Federally unscheduled (state exceptions) | DPT remains unscheduled at the federal level, meaning possession, purchase, and distribution are generally legal under federal law. However, several states have independently scheduled the substance: Florida classifies it as Schedule I, Maine lists it as Schedule X, and Oklahoma has placed it in Schedule I. The Federal Analogue Act may apply if sold for human consumption. |
Harm Reduction
drugs.wikiHarm‑reduction relevant facts and warnings: 1) Dosage and time-course are strongly route-dependent; the widely-circulated 1–2 h total duration is only true for smoked freebase—insufflated and IM commonly last 3–4 h with 2–4 h after-effects. Plan set, setting, and sitter time accordingly. 2) Smoked/vaporized use requires the freebase; DPT salts (e.g., HCl) are unsuitable for vaporization and may decompose under heat. Do not attempt to smoke salts. 3) Nasal administration often causes significant burning, tearing, and congestion; splitting doses, gentle saline rinses post‑session, and avoiding damaged mucosa may reduce harm, but the irritation can still be severe. Experienced users and Erowid’s primer emphasize the substance can be physically and psychologically intense even at seemingly modest insufflated doses. 4) Intramuscular use should only be attempted with sterile technique: use new sterile syringes/needles, sterile diluent, appropriate filtration, skin prep, and never share or reuse injection equipment. Rotate sites and avoid intravenous injection. Community injection HR guides stress these basics to reduce infection and tissue injury. 5) Individual sensitivity varies widely; steep dose–response is reported. Start low, especially with new batches or ROAs. Erowid collations and TIHKAL describe effective IM ranges as low as 15–30 mg and very challenging experiences above ~50–75 mg. 6) Combining DPT with MAOIs (or MAOI‑like drugs) can unpredictably potentiate effects and increase risk of hypertensive or serotonergic crises; avoid this combination. TripSit’s combo guidance flags MAOIs with psychedelics as dangerous. 7) DXM and tramadol are unsafe with serotonergic psychedelics due to seizure and serotonin syndrome risk; avoid. 8) Lithium has a history of severe adverse reactions with classical psychedelics (including seizures); although data are LSD‑focused, prudence dictates avoiding lithium with DPT. 9) DPT appears weakly active orally; if taken this way, expect slower onset, higher dose requirements, more nausea/body‑load, and longer after‑effects. Many prefer non‑oral ROAs for more predictable results. 10) Verify identity: indole tryptamines generally react purple with Ehrlich reagent, which confirms an indole but not the specific compound; only lab testing can confirm identity and purity. 11) Psychological effects can be extremely intense (ego dissolution, fear, tremor); a trusted sober sitter, quiet environment, and clear intention reduce risk of panic and accidents. Erowid’s primer explicitly cautions that DPT is not for casual/recreational mindsets. 12) Tolerance: like other serotonergic psychedelics, acute tolerance develops rapidly and cross‑tolerance with other psychedelics is expected; many harm‑reduction sources recommend at least 1–2 weeks between substantial experiences for baseline sensitivity. DMT may be an exception, but DPT’s longer action suggests ordinary psychedelic tolerance patterns. This guideline is precautionary. 13) Cardiovascular stimulation (transient increases in heart rate/blood pressure), tremor, nausea, and anxiety are commonly reported; those with significant cardiovascular, seizure, or severe psychiatric histories should avoid or take extra precautions in clinical settings. This is a cautious extrapolation from psychedelic HR literature and DPT user reports. 14) Statements sometimes seen online that DPT is “less prone to lasting psychological trauma than LSD or psilocybin” are not evidence-based; reports span from blissful to profoundly challenging. Treat DPT as at least as psychologically powerful as other classic psychedelics.
References
Data Sources
Cited References
- Erowid: DPT Vault
- Fantegrossi et al. 2008 - Hallucinogen-like effects of DPT (DOI)
- Grof et al. 1973 - DPT as an Adjunct in Psychotherapy of Alcoholics (DOI)
- Li et al. 2007 - Behavioral effects of dipropyltryptamine in rats (DOI)
- Richards et al. 1977 - The Peak Experience Variable in DPT-Assisted Psychotherapy (DOI)
- Smith et al. 2014 - Tolerance and Cross-Tolerance to Hallucinogens (DOI)
- Bluelight: DPT Discussion
Drugs.wiki References
- Erowid DPT Main Vault
- Erowid DPT Dosage Page
- Erowid DPT Primer
- TIHKAL #9 DPT (Shulgin)
- PubChem CID 6091 – N,N-Dipropyltryptamine
- TripSit Drug Combinations (general psychedelics + MAOIs/DXM/tramadol cautions)
- Bluelight Injection HR Megathread (sterile technique basics)
- Erowid LSD Interactions – Lithium warning (extrapolated caution to DPT)
- Erowid Crew Blog – Ehrlich reagent and indole reactions